These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 19737541

  • 21. The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.
    Ezzoukhry Z, Louandre C, François C, Saidak Z, Godin C, Mazière JC, Galmiche A.
    Mol Pharmacol; 2011 Jun; 79(6):997-1004. PubMed ID: 21393385
    [Abstract] [Full Text] [Related]

  • 22. [Progress in small-molecule inhibitors of Bcl-2 family proteins].
    Tang Y, Zhang DY, Wu XM.
    Yao Xue Xue Bao; 2008 Jul; 43(7):669-77. PubMed ID: 18819468
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.
    de Graaff MA, de Rooij MA, van den Akker BE, Gelderblom H, Chibon F, Coindre JM, Marino-Enriquez A, Fletcher JA, Cleton-Jansen AM, Bovée JV.
    Br J Cancer; 2016 May 24; 114(11):1219-26. PubMed ID: 27140314
    [Abstract] [Full Text] [Related]

  • 24. Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.
    Yin S, Dong Y, Li J, Fan L, Wang L, Lu J, Vang O, Hu H.
    Apoptosis; 2012 Apr 24; 17(4):388-99. PubMed ID: 22179721
    [Abstract] [Full Text] [Related]

  • 25. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.
    Zheng L, Yang W, Zhang C, Ding WJ, Zhu H, Lin NM, Wu HH, He QJ, Yang B.
    Cancer Lett; 2011 Oct 01; 309(1):27-36. PubMed ID: 21664043
    [Abstract] [Full Text] [Related]

  • 26. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
    Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD, Grigg AP, Seymour JF, Szer J, Huang DC, Roberts AW.
    Leukemia; 2009 Nov 01; 23(11):2034-41. PubMed ID: 19641525
    [Abstract] [Full Text] [Related]

  • 27. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
    Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, Deckwirth T, Frost DJ, Jarvis K, Joseph MK, Marsh K, McClellan W, Nellans H, Ng S, Nimmer P, O'Connor JM, Oltersdorf T, Qing W, Shen W, Stavropoulos J, Tahir SK, Wang B, Warner R, Zhang H, Fesik SW, Rosenberg SH, Elmore SW.
    Cancer Res; 2006 Sep 01; 66(17):8731-9. PubMed ID: 16951189
    [Abstract] [Full Text] [Related]

  • 28. p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737.
    Tagscherer KE, Fassl A, Sinkovic T, Combs SE, Roth W.
    Apoptosis; 2012 Feb 01; 17(2):187-99. PubMed ID: 22002102
    [Abstract] [Full Text] [Related]

  • 29. Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A.
    Cippà PE, Kamarashev J, Chen J, Kraus AK, Segerer S, Feldmeyer L, Fehr T.
    Apoptosis; 2013 Mar 01; 18(3):315-23. PubMed ID: 23208368
    [Abstract] [Full Text] [Related]

  • 30. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.
    Jain HV, Meyer-Hermann M.
    Cancer Res; 2011 Feb 01; 71(3):705-15. PubMed ID: 21169413
    [Abstract] [Full Text] [Related]

  • 31. ABT-737 accelerates butyrate-induced death of HL-60 cells. Involvement of mitochondrial apoptosis pathway.
    Stefaniková A, Kliková K, Hatok J, Račay P.
    Gen Physiol Biophys; 2013 Dec 01; 32(4):505-16. PubMed ID: 23940089
    [Abstract] [Full Text] [Related]

  • 32. Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins.
    Yang C, Chen S, Zhou M, Li Y, Li Y, Zhang Z, Liu Z, Ba Q, Li J, Wang H, Yan X, Ma D, Wang R.
    ChemMedChem; 2014 Jul 01; 9(7):1436-52. PubMed ID: 24782462
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis.
    Lawlor KE, Smith SD, van Nieuwenhuijze A, Huang DC, Wicks IP.
    J Leukoc Biol; 2011 Oct 01; 90(4):819-29. PubMed ID: 21719460
    [Abstract] [Full Text] [Related]

  • 34. Bcl-2 family proteins are essential for platelet survival.
    Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, Iciek LA, Morgan SJ, Nasarre MC, Nelson R, Preusser LC, Reinhart GA, Smith ML, Rosenberg SH, Elmore SW, Tse C.
    Cell Death Differ; 2007 May 01; 14(5):943-51. PubMed ID: 17205078
    [Abstract] [Full Text] [Related]

  • 35. The power and potential of doxorubicin-DNA adducts.
    Cutts SM, Nudelman A, Rephaeli A, Phillips DR.
    IUBMB Life; 2005 Feb 01; 57(2):73-81. PubMed ID: 16036566
    [Abstract] [Full Text] [Related]

  • 36. Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.
    Mathieu AL, Sperandio O, Pottiez V, Balzarin S, Herlédan A, Elkaïm JO, Fogeron ML, Piveteau C, Dassonneville S, Deprez B, Villoutreix BO, Bonnefoy N, Leroux F.
    J Biomol Screen; 2014 Aug 01; 19(7):1035-46. PubMed ID: 24809353
    [Abstract] [Full Text] [Related]

  • 37. Killing cancer cells by flipping the Bcl-2/Bax switch.
    Cory S, Adams JM.
    Cancer Cell; 2005 Jul 01; 8(1):5-6. PubMed ID: 16023593
    [Abstract] [Full Text] [Related]

  • 38. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.
    Reynoso D, Nolden LK, Yang D, Dumont SN, Conley AP, Dumont AG, Zhou K, Duensing A, Trent JC.
    Mol Oncol; 2011 Feb 01; 5(1):93-104. PubMed ID: 21115411
    [Abstract] [Full Text] [Related]

  • 39. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance.
    van Oosterwijk JG, Herpers B, Meijer D, Briaire-de Bruijn IH, Cleton-Jansen AM, Gelderblom H, van de Water B, Bovée JV.
    Ann Oncol; 2012 Jun 01; 23(6):1617-26. PubMed ID: 22112972
    [Abstract] [Full Text] [Related]

  • 40. Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction.
    Lickliter JD, Cox J, McCarron J, Martinez NR, Schmidt CW, Lin H, Nieda M, Nicol AJ.
    Br J Cancer; 2007 Feb 26; 96(4):600-8. PubMed ID: 17311012
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.